Comparative Pharmacology
Head-to-head clinical analysis: BETAXON versus DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAXON versus DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE.
BETAXON vs DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production through inhibition of beta-1 receptors in the ciliary epithelium.
Dorzolamide is a carbonic anhydrase inhibitor that reduces aqueous humor secretion by inhibiting carbonic anhydrase in the ciliary processes. Timolol is a non-selective beta-adrenergic receptor antagonist that reduces aqueous humor production by blocking beta-2 adrenergic receptors in the ciliary epithelium.
0.25% ophthalmic solution, 1 drop in the affected eye(s) twice daily.
One drop of the fixed combination (dorzolamide 22.26 mg/mL, timolol 6.83 mg/mL) in the affected eye(s) every 12 hours.
None Documented
None Documented
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 36 hours).
Dorzolamide: ~4 months but accumulates in RBCs; terminal half-life ~4-5 months due to binding to carbonic anhydrase. Timolol: ~4-6 hours.
Primarily renal (40-50% unchanged) and fecal (30-40% as metabolites); biliary excretion contributes minimally.
Dorzolamide: primarily renal (approx. 80% unchanged), with minor biliary/fecal elimination. Timolol: renal (15-20% unchanged) and extensive hepatic metabolism with fecal excretion.
Category C
Category A/B
Beta-Blocker
Beta-Blocker